<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025791</url>
  </required_header>
  <id_info>
    <org_study_id>8266-001</org_study_id>
    <secondary_id>MK-8266-001</secondary_id>
    <secondary_id>2009_700</secondary_id>
    <secondary_id>2009-015774-36</secondary_id>
    <nct_id>NCT01025791</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of MK-8266 (MK-8266-001)</brief_title>
  <official_title>A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8266</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A three panel study, to determine if MK-8266 given as a single dose is sufficiently safe and
      well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of
      subjects with mild to moderate hypertension. The primary hypotheses for the study are that
      MK-8266 given as single doses is sufficiently safe and well tolerated to permit continued
      clinical investigation in healthy young male volunteers and male participants with
      mild-to-moderate hypertension and that in males with mild to moderate hypertension, at a
      single oral dose of MK-8266 that is sufficiently safe and well-tolerated, postdose mean
      time-weighted average across 24 hours of aortic augmentation index (TWA0-12hrs AIx) is
      reduced compared to placebo. A mean decrease of ≥ 5 percentage points is considered
      clinically meaningful.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three panels, each consisting of either 8 or 9 participants (8 healthy young males in Panel A
      and Panel B; and 9 participants with mild to moderate hypertension in Panel C) will be
      randomized to receive either MK-8266 or matching placebo in either a 6:2 ratio (Panel A and
      Panel B) or 6:3 ratio (Panel C), respectively, in up to 5 treatment (1 to 5) periods in Panel
      A and up to 4 treatment (1 to 4) periods in Panel B and Panel C. In all panels, doses will be
      escalated in a rising, fixed sequence. Some participants took study drug after fasting and
      some with food.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2009</start_date>
  <completion_date type="Actual">May 14, 2010</completion_date>
  <primary_completion_date type="Actual">May 14, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events</measure>
    <time_frame>Up to 14 days after administration of last dose of study drug in each study period (Up to 43 Days)</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to 43 days</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic Augmentation Index - Time-Weighted Average 0-24 Hours</measure>
    <time_frame>Predose, 1.5, 3, 12, and 24 hours postdose</time_frame>
    <description>Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-inf] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC[0-inf] was not collected, analyzed or summarized for participants receiving placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MK-8266 PK Parameter Apparent t1/2</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-24 hours] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</measure>
    <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average of Heart Rate (0-12 Hours)</measure>
    <time_frame>Up to 12 hours</time_frame>
    <description>HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8266 0.1 mg</intervention_name>
    <description>Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.</description>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 1</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 2</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 3</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 5</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 6</arm_group_label>
    <other_name>MK-8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8266 1.0 mg</intervention_name>
    <description>MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.</description>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 1</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 2</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 3</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 5</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.</description>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 3</arm_group_label>
    <arm_group_label>Panel A, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 1</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 2</arm_group_label>
    <arm_group_label>Panel B, Healthy Male Participants, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 2</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 3</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 4</arm_group_label>
    <arm_group_label>Panel C, Mild/Moderate Hypertension, Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Panel A and B Participant is a healthy male between 18 to 45 years of age. For
             Panel C Participant is a male with essential hypertension between 18 to 55 years of
             age

          -  A non-smoker

        Exclusion Criteria:

          -  Has a history of stroke, chronic seizure or major neurological disorder

          -  Has a disability that can interfere with rising from a sitting position to the
             standing position

          -  Has a personal of family history of bleeding or clotting disorders

          -  Has a history of cancer

          -  Is unable to refrain from or anticipates the use of any prescription or
             nonprescription drug during the study

          -  Consumes excessive amounts of caffeine or alcohol

          -  Has had major surgery, donated blood or participated in another investigational study
             in the past 4 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>February 5, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2019</results_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 2 clinical study sites in Germany and in Belgium.</recruitment_details>
      <pre_assignment_details>For Panel A, 5 treatment periods were planned in this study. For Panels B and C, only 4 treatment periods were planned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel A, Healthy Male Participants, Sequence 1</title>
          <description>MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
        </group>
        <group group_id="P2">
          <title>Panel A, Healthy Male Participants, Sequence 2</title>
          <description>MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
        </group>
        <group group_id="P3">
          <title>Panel A, Healthy Male Participants, Sequence 3</title>
          <description>MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.</description>
        </group>
        <group group_id="P4">
          <title>Panel A, Healthy Male Participants, Sequence 4</title>
          <description>MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
        </group>
        <group group_id="P5">
          <title>Panel B, Healthy Male Participants, Sequence 1</title>
          <description>MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.</description>
        </group>
        <group group_id="P6">
          <title>Panel B, Healthy Male Participants, Sequence 2</title>
          <description>MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.</description>
        </group>
        <group group_id="P7">
          <title>Panel B, Healthy Male Participants, Sequence 3</title>
          <description>MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.</description>
        </group>
        <group group_id="P8">
          <title>Panel B, Healthy Male Participants, Sequence 4</title>
          <description>MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.</description>
        </group>
        <group group_id="P9">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 1</title>
          <description>Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
        </group>
        <group group_id="P10">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 2</title>
          <description>Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na</description>
        </group>
        <group group_id="P11">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 3</title>
          <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
        </group>
        <group group_id="P12">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 4</title>
          <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na</description>
        </group>
        <group group_id="P13">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 5</title>
          <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
        </group>
        <group group_id="P14">
          <title>Panel C, Mild/Moderate Hypertension, Sequence 6</title>
          <description>Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panel A MK-8266 (Healthy Males)</title>
          <description>MK-8266 single dose or placebo matching MK-8266 in healthy male participants in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.</description>
        </group>
        <group group_id="B2">
          <title>Panel B MK-8266 (Healthy Males)</title>
          <description>MK-8266 single dose or placebo matching MK-8266 in healthy male participants in Periods 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.</description>
        </group>
        <group group_id="B3">
          <title>Panel C MK-8266 (Mild/Mod. Hypertension)</title>
          <description>MK-8266 single dose or placebo matching MK-8266 (Mild/Mod. Hypertension) in Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="8.1"/>
                    <measurement group_id="B2" value="27.3" spread="5.4"/>
                    <measurement group_id="B3" value="47.3" spread="3.9"/>
                    <measurement group_id="B4" value="36.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced One or More Adverse Events</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
        <time_frame>Up to 14 days after administration of last dose of study drug in each study period (Up to 43 Days)</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-8266 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-8266 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-8266 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-8266 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O14">
            <title>Pooled Placebo (Panels A, B, C)</title>
            <description>Placebo matching MK-8266.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced One or More Adverse Events</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
        <time_frame>Up to 43 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-8266 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-8266 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-8266 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-8266 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O14">
            <title>Pooled Placebo (Panels A, B, C)</title>
            <description>Placebo matching MK-8266.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Aortic Augmentation Index - Time-Weighted Average 0-24 Hours</title>
        <description>Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.</description>
        <time_frame>Predose, 1.5, 3, 12, and 24 hours postdose</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Panel B MK-8266 0.4 mg fasted and Panel B MK-8266 0.4 mg fed were combined in the analysis. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-8266 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-8266 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-8266 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel A Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
          <group group_id="O7">
            <title>Pooled Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 0.4 mg in healthy male participants, fasted and fed</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK-8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O10">
            <title>Panel B Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod.</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O14">
            <title>Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O15">
            <title>Panel C Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Augmentation Index - Time-Weighted Average 0-24 Hours</title>
          <description>Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Panel B MK-8266 0.4 mg fasted and Panel B MK-8266 0.4 mg fed were combined in the analysis. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>Percentage of central pulse pressure</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.79" spread="9.66"/>
                    <measurement group_id="O2" value="-2.96" spread="9.15"/>
                    <measurement group_id="O3" value="-1.73" spread="4.49"/>
                    <measurement group_id="O4" value="-7.42" spread="3.85"/>
                    <measurement group_id="O5" value="-5.70" spread="7.57"/>
                    <measurement group_id="O6" value="-1.73" spread="7.36"/>
                    <measurement group_id="O7" value="-13.1" spread="8.71"/>
                    <measurement group_id="O8" value="-14.1" spread="7.49"/>
                    <measurement group_id="O9" value="-16.7" spread="5.21"/>
                    <measurement group_id="O10" value="-15.3" spread="2.68"/>
                    <measurement group_id="O11" value="8.43" spread="4.98"/>
                    <measurement group_id="O12" value="11.29" spread="6.60"/>
                    <measurement group_id="O13" value="7.78" spread="11.10"/>
                    <measurement group_id="O14" value="8.74" spread="3.90"/>
                    <measurement group_id="O15" value="17.74" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
            <param_type>0.1 mg vs. placebo</param_type>
            <param_value>-7.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.1</ci_lower_limit>
            <ci_upper_limit>-3.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <method>ANOVA</method>
            <param_type>0.2 mg vs. placebo</param_type>
            <param_value>-1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.42</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.498</p_value>
            <method>ANOVA</method>
            <param_type>0.5 mg vs. placebo</param_type>
            <param_value>0.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.05</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANOVA</method>
            <param_type>1 mg vs. placebo</param_type>
            <param_value>-5.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.74</ci_lower_limit>
            <ci_upper_limit>-1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 0.8 mg vs. placebo</param_type>
            <param_value>-3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.16</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>ANOVA</method>
            <param_type>0.4 mg vs. placebo</param_type>
            <param_value>2.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg vs. placebo</param_type>
            <param_value>1.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.314</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg + 0.6 mg vs. placebo</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.50</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 0.8 mg vs. placebo</param_type>
            <param_value>-9.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>-4.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg + 1.0 mg vs. placebo</param_type>
            <param_value>-6.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>1.0 mg + 0.6 mg + 0.6 mg vs. placebo</param_type>
            <param_value>-9.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>-5.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 1 mg + 0.6 mg vs. placebo</param_type>
            <param_value>-9.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>-4.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-inf] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC[0-inf] was not collected, analyzed or summarized for participants receiving placebo.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
        <population>AUC[0-inf] was not estimated at MK-8266 doses &lt;1.0 mg and for the first 2 doses in Panel C due to the lack of measureable concentrations, and for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-inf] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC[0-inf] was not collected, analyzed or summarized for participants receiving placebo.</description>
          <population>AUC[0-inf] was not estimated at MK-8266 doses &lt;1.0 mg and for the first 2 doses in Panel C due to the lack of measureable concentrations, and for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>mg/mL*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="264" spread="64.4"/>
                    <measurement group_id="O5" value="441" spread="105"/>
                    <measurement group_id="O7" value="216" spread="55.95"/>
                    <measurement group_id="O8" value="350" spread="49.5"/>
                    <measurement group_id="O12" value="528" spread="151"/>
                    <measurement group_id="O13" value="623" spread="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model. Cmax was not estimated for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model. Cmax was not estimated for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.291"/>
                    <measurement group_id="O2" value="4.33" spread="0.454"/>
                    <measurement group_id="O3" value="11.4" spread="0.819"/>
                    <measurement group_id="O4" value="22.2" spread="3.40"/>
                    <measurement group_id="O5" value="20.5" spread="2.58"/>
                    <measurement group_id="O6" value="7.46" spread="1.41"/>
                    <measurement group_id="O7" value="19.5" spread="5.14"/>
                    <measurement group_id="O8" value="21.3" spread="4.16"/>
                    <measurement group_id="O9" value="7.71" spread="2.64"/>
                    <measurement group_id="O10" value="19.1" spread="3.77"/>
                    <measurement group_id="O11" value="22.1" spread="3.06"/>
                    <measurement group_id="O12" value="21.7" spread="3.80"/>
                    <measurement group_id="O13" value="22.4" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
        <population>The analysis population consisted of participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Tmax was not estimated for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.</description>
          <population>The analysis population consisted of participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Tmax was not estimated for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.5" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="4.0" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="O5" value="3.5" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O7" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O8" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O9" value="1.5" lower_limit="1.5" upper_limit="6.0"/>
                    <measurement group_id="O10" value="3.0" lower_limit="2.0" upper_limit="10.0"/>
                    <measurement group_id="O11" value="5.0" lower_limit="3.0" upper_limit="10.0"/>
                    <measurement group_id="O12" value="6.5" lower_limit="2.0" upper_limit="15.0"/>
                    <measurement group_id="O13" value="9.0" lower_limit="3.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MK-8266 PK Parameter Apparent t1/2</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
        <population>t1/2 was not estimated at MK-8266 doses below 1 mg and for the first 2 doses in Panel C due to the lack of measureable concentrations and for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-826 6 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O7">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
          <group group_id="O10">
            <title>Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
        </group_list>
        <measure>
          <title>MK-8266 PK Parameter Apparent t1/2</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.</description>
          <population>t1/2 was not estimated at MK-8266 doses below 1 mg and for the first 2 doses in Panel C due to the lack of measureable concentrations and for participants receiving placebo. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="13.6" spread="2.6"/>
                    <measurement group_id="O5" value="11.7" spread="2.2"/>
                    <measurement group_id="O7" value="9.2" spread="3.5"/>
                    <measurement group_id="O8" value="12.0" spread="3.0"/>
                    <measurement group_id="O12" value="10.4" spread="2.2"/>
                    <measurement group_id="O13" value="12.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-24 hours] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 postdose</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-24 hours] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>nM·hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="38.9" upper_limit="91.2"/>
                    <measurement group_id="O2" value="52.9" lower_limit="34.6" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Fed/Fasted)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.</description>
        <time_frame>Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
            <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.2" upper_limit="11.0"/>
                    <measurement group_id="O2" value="7.3" lower_limit="5.0" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR (Fed/fasted)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average of Heart Rate (0-12 Hours)</title>
        <description>HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
        <time_frame>Up to 12 hours</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Panel B MK-8266 0.4 mg fasted and Panel B MK-8266 0.4 mg fed were combined in the analysis. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
            <description>MK-8266 single 0.1 mg dose in healthy male participants</description>
          </group>
          <group group_id="O2">
            <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
            <description>MK-8266 single 0.2 mg dose in healthy male participants</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
            <description>MK-8266 single 0.5 mg dose in healthy male participants</description>
          </group>
          <group group_id="O4">
            <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose in healthy male participants</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
          </group>
          <group group_id="O6">
            <title>Panel A Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
          <group group_id="O7">
            <title>Pooled Panel B MK-8266 0.4 mg (Healthy Males)</title>
            <description>MK- 8266 single dose 0.4 mg in healthy male participants, fasted and fed</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
            <description>MK-8266 single dose 1.2 mg in healthy male participants</description>
          </group>
          <group group_id="O9">
            <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
            <description>MK-826 6 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
          </group>
          <group group_id="O10">
            <title>Panel B Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod.</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O14">
            <title>Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
            <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
          </group>
          <group group_id="O15">
            <title>Panel C Placebo</title>
            <description>Placebo to MK-8266</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average of Heart Rate (0-12 Hours)</title>
          <description>HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that their data likely exhibited the effects of treatment. Panel B MK-8266 0.4 mg fasted and Panel B MK-8266 0.4 mg fed were combined in the analysis. One participant in Panel B 1.2 mg + 0.6 mg did not receive the 1.2 mg dose and was not included in this analysis.</population>
          <units>Beats per Minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.79" spread="6.71"/>
                    <measurement group_id="O2" value="61.65" spread="3.06"/>
                    <measurement group_id="O3" value="56.36" spread="4.86"/>
                    <measurement group_id="O4" value="66.40" spread="7.90"/>
                    <measurement group_id="O5" value="63.71" spread="3.17"/>
                    <measurement group_id="O6" value="59.32" spread="6.28"/>
                    <measurement group_id="O7" value="57.38" spread="5.92"/>
                    <measurement group_id="O8" value="61.07" spread="5.04"/>
                    <measurement group_id="O9" value="59.92" spread="10.23"/>
                    <measurement group_id="O10" value="56.53" spread="6.66"/>
                    <measurement group_id="O11" value="69.82" spread="8.09"/>
                    <measurement group_id="O12" value="66.40" spread="9.82"/>
                    <measurement group_id="O13" value="64.14" spread="7.40"/>
                    <measurement group_id="O14" value="64.90" spread="8.33"/>
                    <measurement group_id="O15" value="60.66" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.396</p_value>
            <method>ANOVA</method>
            <param_type>0.1 mg vs placebo</param_type>
            <param_value>-0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.92</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1329</p_value>
            <method>ANOVA</method>
            <param_type>0.2 mg vs. placebo</param_type>
            <param_value>2.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0741</p_value>
            <method>ANOVA</method>
            <param_type>0.5mg vs. placebo</param_type>
            <param_value>-2.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.35</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>1 mg vs. placebo</param_type>
            <param_value>7.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.69</ci_lower_limit>
            <ci_upper_limit>10.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0211</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 0.8 mg vs. placebo</param_type>
            <param_value>4.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>7.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>ANOVA</method>
            <param_type>0.4 mg vs. placebo</param_type>
            <param_value>0.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>6.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg vs. placebo</param_type>
            <param_value>4.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.94</ci_lower_limit>
            <ci_upper_limit>11.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg + 0.6 mg vs. placebo</param_type>
            <param_value>3.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.29</ci_lower_limit>
            <ci_upper_limit>10.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANOVA</method>
            <param_type>1.0 mg + 0.8 mg vs. placebo</param_type>
            <param_value>9.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.74</ci_lower_limit>
            <ci_upper_limit>16.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>ANOVA</method>
            <param_type>1.2 mg + 1.0 mg vs. placebo</param_type>
            <param_value>5.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>13.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.214</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 0.6 mg + 0.6 mg vs. placebo</param_type>
            <param_value>3.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.94</ci_lower_limit>
            <ci_upper_limit>10.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>ANOVA</method>
            <param_type>1 mg + 1 mg + 0.6 mg vs. placebo</param_type>
            <param_value>4.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.03</ci_lower_limit>
            <ci_upper_limit>11.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after administration of the last dose of study drug (Up to 43 days)</time_frame>
      <desc>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population consisted of all participants who received at least one dose of the investigational drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panel A MK-8266 0.1 mg (Healthy Males)</title>
          <description>MK-8266 single 0.1 mg dose in healthy male participants</description>
        </group>
        <group group_id="E2">
          <title>Panel A MK-8266 0.2 mg (Healthy Males)</title>
          <description>MK-8266 single 0.2 mg dose in healthy male participants</description>
        </group>
        <group group_id="E3">
          <title>Panel A MK-8266 0.5 mg (Healthy Males)</title>
          <description>MK-8266 single 0.5 mg dose in healthy male participants</description>
        </group>
        <group group_id="E4">
          <title>Panel A MK-8266 1.0 mg (Healthy Males)</title>
          <description>MK-8266 single 1.0 mg dose in healthy male participants</description>
        </group>
        <group group_id="E5">
          <title>Panel A MK-8266 1.0/0.8 mg (Healthy Males)</title>
          <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.8 mg dose in healthy male participants</description>
        </group>
        <group group_id="E6">
          <title>Panel B MK-8266 0.4 mg (Healthy Males)</title>
          <description>MK-8266 single dose 0.4 mg in healthy male participants</description>
        </group>
        <group group_id="E7">
          <title>Panel B MK-8266 1.2 mg (Healthy Males)</title>
          <description>MK- 8266 single dose 1.2 mg in healthy male participants</description>
        </group>
        <group group_id="E8">
          <title>Panel B MK-8266 1.2/0.6 mg (Healthy Males)</title>
          <description>MK-8266 single 1.2 mg followed in 6 hours by a 0.6 mg dose in healthy male participants</description>
        </group>
        <group group_id="E9">
          <title>Panel B MK-8266 0.4 mg Fed (Healthy Males)</title>
          <description>MK-8266 single 0.4 mg dose in healthy male participants, fed.</description>
        </group>
        <group group_id="E10">
          <title>Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)</title>
          <description>MK-8266 single 1.0 mg dose followed in 8 hours by a 0.8 mg dose in participants with mild/mod. hypertension</description>
        </group>
        <group group_id="E11">
          <title>Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)</title>
          <description>MK-8266 single 1.2 mg dose followed in 8 hours by a 1.0 mg dose in participants with mild/mod. hypertension</description>
        </group>
        <group group_id="E12">
          <title>Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)</title>
          <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
        </group>
        <group group_id="E13">
          <title>Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)</title>
          <description>MK-8266 single 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose in participants with mild/mod. hypertension</description>
        </group>
        <group group_id="E14">
          <title>Pooled Placebo (Panels A, B, C)</title>
          <description>Placebo matching MK-8266.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Orthostatic heart rate response increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" events="8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E14" events="9" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

